Abstract 5019
Background
The introduction of trastuzumab in combination with chemotherapy has significantly improved clinical outcomes for patients with HER2-positive breast cancer. HLX02 was developed as a trastuzumab biosimilar with the potential to increase market competition and treatment accessibility in China and around the world.
Methods
We conducted a randomised, double-blind, parallel-controlled equivalence study (HLX02-BC01) at 89 study centres in China, Philippines, Poland and Ukraine. Eligible women were aged 18 years or older, had histologically confirmed HER2+ breast cancer, an Eastern Cooperative Oncology Group performance status of 0 to 1, and estimated life expectancy ≥3 months. Patients were randomised at 1:1 to receive an intravenous dose of 8 mg/kg of HLX02 or EU-trastuzumab with docetaxel on Day 1 -Cycle 1 followed by a dose of 6 mg/kg once every 3 weeks in 3-weekly cycles for up to a maximum of 12 months. The primary endpoint was best overall response rate at Week 24 (ORRwk24) evaluated by blinded central imaging review. Secondary endpoints included clinical benefit rate (CBR), disease control rate (DCR), duration of response (DoR), progression-free survival (PFS) and overall survival (OS), safety outcomes with immunogenicity and incidence of adverse events up to 12 months.
Results
Of 1046 patients enrolled, 649 were randomly allocated to receive HLX02 (n = 324) or EU-trastuzumab (n = 325). The ORR was 71.0% (230 of 324 patients; 95% CI: 66.0, 75.9) for HLX02 and 71.4% (232 of 325 patients; 95% CI: 66.5, 76.3) for EU-trastuzumab. The p-value at 95% CI (p = 0.952) was completely contained within the pre-defined equivalence boundaries of ± 13.5%. The difference in ORR between the 2 treatments was 0.4 (95% CI: -7.4, 6.6). Safety outcomes and immunogenicity were similar between the treatment groups at Week 24.
Conclusions
Among women with HER2+ metastatic breast cancer, the use of HLX02 compared with EU-trastuzumab resulted in an equivalent ORR at Week 24. All secondary efficacy and safety analyses at Week 24 also supported the conclusion of therapeutic equivalence; HLX02 does not demonstrate new safety signals in comparison with EU-trastuzumab. Further study results at Month 12 will be reported in August once the study is unblinded.
Clinical trial identification
NCT03084237; EudraCT: 2016-000206-10.
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Henlius Biotech, Inc.
Funding
Shanghai Henlius Biotech, Inc.
Disclosure
B. Xu: Research grant / Funding (institution): Shanghai Henlius Biotech,Inc. Q. Zhang: Research grant / Funding (institution): Shanghai Henlius Biotech,Inc. T. Sun: Research grant / Funding (institution): Shanghai Henlius Biotech,Inc. W. Li: Research grant / Funding (institution): Shanghai Henlius Biotech,Inc. Y. Teng: Research grant / Funding (institution): Shanghai Henlius Biotech,Inc. X. Hu: Research grant / Funding (institution): Shanghai Henlius Biotech,Inc. I. Bondarenko: Research grant / Funding (institution): Shanghai Henlius Biotech,Inc. H. Adamchuk: Research grant / Funding (institution): Shanghai Henlius Biotech,Inc. L. Zhang: Research grant / Funding (institution): Shanghai Henlius Biotech,Inc. D. Trukhin: Research grant / Funding (institution): Shanghai Henlius Biotech,Inc. B. Li: Full / Part-time employment: Shanghai Henlius Biotech,Inc. B. Shan: Full / Part-time employment: Shanghai Henlius Biotech,Inc. J. Cheng: Full / Part-time employment: Shanghai Henlius Biotech,Inc. T. Peng: Full / Part-time employment: Shanghai Henlius Biotech,Inc. W. Jiang: Full / Part-time employment: Shanghai Henlius Biotech,Inc. S. Liu: Full / Part-time employment: Shanghai Henlius Biotech,Inc. X. Zhang: Full / Part-time employment: Shanghai Henlius Biotech,Inc. Q. Wang: Full / Part-time employment: Shanghai Henlius Biotech, Inc. E. Liu: Full / Part-time employment: Henlix Biotech, Inc. A.Y. Luk: Full / Part-time employment: Shanghai Henlius Biotech,Inc.
Resources from the same session
1911 - PIK3CA Alterations in Metastatic Breast Cancer (mBC)
Presenter: Joan Albanell
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Abstract
4351 - Emergence of ESR1 mutation in cell-free DNA during first line aromatase inhibitor and palbociclib: an exploratory analysis of the PADA-1 trial
Presenter: Francois-Clement Bidard
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Abstract
3596 - Updated overall survival (OS) and quality of life (QoL) in premenopausal patients (pts) with advanced breast cancer (ABC) who received ribociclib (RIB) or placebo (PBO) plus goserelin and a nonsteroidal aromatase inhibitor (NSAI) in the MONALEESA-7 (ML-7) trial
Presenter: Yen-Shen Lu
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Abstract
1216 - The importance of primary surgery in patients with de novo stage IV BC survived at least 5- Year; Protocol MF07-01 Randomized Clinical Trial.
Presenter: Vahit Ozmen
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Abstract
2713 - Leuprorelin (LEUP) combined with Letrozole (LET) with/without Everolimus (EVE) in Ovarian suppressed premenopausal women with hormone receptor (HR) positive, HER2-negative metastatic breast cancer (MBC): Primary analysis of LEO Trial (NCT02344550)
Presenter: Jaeho Jeong
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Abstract
Poster Discussion - Breast cancer, metastatic - Invited Discussant 306PD and 307PD
Presenter: Aleix Prat
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Slides
Webcast
1589 - Patient-reported outcomes of palbociclib plus exemestane with GnRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer from the YoungPearl phase ll trial (KCSG-BR 15-10, NCT02592746)
Presenter: Soohyeon Lee
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Abstract
Poster Discussion - Breast cancer, metastatic - Invited Discussant LBA24 and 308PD
Presenter: Alexandru Eniu
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Slides
Webcast
Poster Discussion - Breast cancer, metastatic - Invited Discussant 309PD and 310PD
Presenter: Sherko Kümmel
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Slides
Webcast
1076 - MONARCHplus: A Phase 3 Trial of Abemaciclib plus Nonsteroidal Aromatase Inhibitor (NSAI) or Fulvestrant (F) for Women with HR+/HER2- Advanced Breast Cancer (ABC)
Presenter: Zefei Jiang
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Abstract